Dr. Capanu’s current methodological research interests are in the development of optimized variable selection procedures for regression models. She has recently developed a novel variable selection technique and showed that it has superior performance to competitor methods for low to moderate scale linear regressions. As part of her collaborative work, Dr. Capanu has been involved in clinical collaborations with the Gastrointestinal Oncology Service since joining Memorial Sloan Kettering Cancer Center in 2005. She has assisted the oncologists in this group at every stage in their clinical trials from the design to the statistical analysis and publication of their studies. Dr. Capanu is also assisting investigators in the Department of Radiology with the design and analysis of various projects investigating different imaging modalities and potential biomarkers.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Marinela Capanu discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures